Dara-RVd
Showing 1 - 25 of 65
High-risk Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- High-risk Smoldering Multiple Myeloma
- Multiple Myeloma
- Daratumumab
- +3 more
-
Boston, Massachusetts
- +1 more
Oct 18, 2021
Multiple Myeloma Trial in United States (bb2121, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Multiple Myeloma
- bb2121
- +3 more
-
Scottsdale, Arizona
- +19 more
Jul 7, 2022
Clinical Pathways for Newly Diagnosed Multiple Myeloma
Not yet recruiting
- Multiple Myeloma
- Multiple Myeloma Without Mention of Remission
- Multiple Myeloma Pathway
- +2 more
- (no location specified)
Nov 27, 2023
Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)
Not yet recruiting
- Multiple Myeloma
- Teclistamab
- +2 more
-
Miami, FloridaUniversity of Miami
Oct 20, 2023
Multiple Myeloma, Renal Failure Trial in Augusta (Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide,
Not yet recruiting
- Multiple Myeloma
- Renal Failure
- Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
-
Augusta, GeorgiaGeorgia Cancer Center-Augusta University
Nov 16, 2023
High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)
Not yet recruiting
- High-Risk de Novo Multiple Myeloma
- Daratumumab
- +5 more
-
Badalona, Spain
- +9 more
Apr 27, 2023
Multiple Myeloma Trial in Worldwide (Dara SC, Dara IV)
Active, not recruiting
- Multiple Myeloma
- Dara SC
- Dara IV
-
Boston, Massachusetts
- +145 more
Jan 17, 2023
Chronic Heart Failure, Right Ventricular Dysfunction, Right Heart Failure Trial in Italy (Echocardiography, Laboratory Test)
Not yet recruiting
- Chronic Heart Failure
- +2 more
- Echocardiography
- Laboratory Test
-
Milan, Milano, Italy
- +13 more
Aug 18, 2023
Acute Hypoxemic Respiratory Failure Trial in Hong Kong (Transthoracic Echocardiography)
Recruiting
- Acute Hypoxemic Respiratory Failure
- Transthoracic Echocardiography
-
Hong Kong, Hong KongQueen Mary Hospital
Oct 22, 2023
Relapsed or Refractory Multiple Myeloma Trial (Daratumumab, Pomalidomide)
Withdrawn
- Relapsed or Refractory Multiple Myeloma
- (no location specified)
Jan 26, 2023
Pulmonary Embolism, Venous Thromboembolism, Metabolomics Trial in Boston (Oxygen Therapy, Non-rebreather mask)
Not yet recruiting
- Pulmonary Embolism
- +3 more
- Oxygen Therapy
- Non-rebreather mask
-
Boston, MassachusettsMassachusetts General Hospital
May 26, 2023
AL Amyloidosis Trial (procedure, drug, other)
Not yet recruiting
- AL Amyloidosis
- Autologous Hematopoietic Stem Cell Transplantation
- +15 more
- (no location specified)
Aug 28, 2023
Maintenance With Bortezomib Plus Daratumumab After Induction
Recruiting
- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)
-
Arganda Del Rey, Spain
- +31 more
Sep 15, 2022
Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)
Active, not recruiting
- Multiple Myeloma
- Carfilzomib 20 mg/m^2
- +4 more
-
Gilbert, Arizona
- +107 more
Dec 20, 2022
Multiple Myeloma Trial in Torino (Velcade, Melphalan, Prednisone)
Recruiting
- Multiple Myeloma
- Velcade
- +5 more
-
Torino, TO, ItalyDipartimento di Biotecnologie Molecolari e Scienze per la Salute
May 25, 2022
Right Heart Failure, Mechanical Ventilation, Acute Respiratory Distress Syndrome Trial in Wuhan (Airway pressure release
Recruiting
- Right Heart Failure
- +2 more
- Airway pressure release ventilation
- low tidal volume
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Jun 27, 2023
Multiple Myeloma Trial in Worldwide (Daratumumab Subcutaneous (SC) Administration, Recombinant Human Hyaluronidase [rHuPH20]) SC
Active, not recruiting
- Multiple Myeloma
- Daratumumab Subcutaneous (SC) Administration
- Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
-
Atlanta, Georgia
- +11 more
Aug 11, 2022